Michael S. Weiss, Chariman and CEO at KERYX BIOPHARMACEUTICALS INC (KERX), sold 36,500 shares at $17.07 ($624K) on 2006-04-18, disclosed to the SEC on 2006-04-20.
Scheduled sale ($624k) by Chariman and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.03 | 1,000 | $17K | 2.7% |
| 2 | $17.04 | 1,000 | $17K | 2.7% |
| 3 | $17.05 | 2,500 | $43K | 6.8% |
| 4 | $17.05 | 500 | $9K | 1.4% |
| 5 | $17.06 | 4,000 | $68K | 10.9% |
| 6 | $17.06 | 1,000 |
| $17K |
| 2.7% |
| 7 | $17.07 | 1,000 | $17K | 2.7% |
| 8 | $17.07 | 500 | $9K | 1.4% |
| 9 | $17.08 | 1,000 | $17K | 2.7% |
| 10 | $17.08 | 2,000 | $34K | 5.5% |
| 11 | $17.09 | 1,000 | $17K | 2.7% |
| 12 | $17.09 | 5,500 | $94K | 15.1% |
| 13 | $17.10 | 10,500 | $180K | 28.8% |
| 14 | $17.11 | 1,000 | $17K | 2.7% |
| 15 | $17.12 | 3,000 | $51K | 8.2% |
| 16 | $17.25 | 1,000 | $17K | 2.8% |
| Total | $17.09 avg | 36,500 | $624K | 100% |
| Filing → |
| FBIO | BUY | 2023-02-14 | $2.0M | — | Filing → |
| TGTX | SELL | 2022-01-07 | $2.6M | — | Filing → |
| TGTX | BUY | 2019-06-27 | $352K | — | Filing → |